Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer - Related Studies

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

This study is currently recruiting participants.

Study NCT00134004. Last updated on November 13, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia
		Lymphoma
		Myelodysplastic Syndromes

2	Additional conditions recognized in this trial
		Lymphoma, Large-Cell, Immunoblastic
		Lymphoma, Non-Hodgkin
		Multiple Myeloma
		Myeloproliferative Disorders
		Neoplasms, Plasma Cell
		Preleukemia
		Syndrome

3	More general conditions related to this trial
		Blood Protein Disorders
		Bone Marrow Diseases
		Cardiovascular Diseases
		Disease
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Pathologic Processes
		Precancerous Conditions
		Vascular Diseases

4	Interventions listed in this trial
		cyclophosphamide
		fludarabine phosphate
		mycophenolate mofetil
		tacrolimus
		radiation therapy

5	Additional drug interventions recognized in this trial
		Fludarabine
		Fludarabine monophosphate

6	More general drug interventions related to this trial
		Alkylating Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Sidney Kimmel Comprehensive Cancer Center
		National Cancer Institute (NCI)